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At Virginia Commonwealth University Health System, he-
matopoietic cell transplant (HCT) patients receive proton
pump inhibitors (PPI) during their admission to prevent
chemotherapy-induced gastroduodenal injury. Prior to 2012,
most patients were also discharged on PPI to reduce the
frequency of ulcers and upper gastrointestinal (GI) symp-
toms after HCT.
Adverse effects of PPI therapy may include magnesium
deﬁciency, 1,2 increases in Clostridium difﬁcile infection,3 and
an increased risk of community-acquired pneumonia.4
Compared to PPI therapy, H-2 receptor antagonists (H2RA)
have less pronounced and prolonged acid suppressionwhich
contributes to an advantageous side effect proﬁle. Since HCT
patients are subject to low electrolyte levels5 and increased
risks of infection at baseline, we sought to determine the
association between PPI use and electrolyte repletion and
infection rates and whether the use of H2RA was associated
with reduced risk of these complications.
A retrospective, matched cohort study was conducted
from September 30, 2010 through March 31, 2013. Patients
18 years or older receiving H2RA therapy post-HCT
admission were matched by transplant type and prepara-
tory regimen to patients receiving PPI. Matched pairs were
evaluated for four weeks post-discharge. In addition to
baseline characteristics, data collected included the
amount and frequency of electrolyte repletion via a stan-
dard institutional protocol, rates of infection (positive
cultures, use of antibiotics, radiologic evidence of pneu-
monia), and patient-reported GI symptoms. Data were
analyzed with descriptive statistics, paired t-tests, and
McNemar’s Chi square test.
Twenty-six matched pairs were included. Patients receiving
PPI required signiﬁcantly more magnesium repletion in
weeks 1, 3, and 4 post-discharge. During weeks 1, 3, and 4,
signiﬁcantly more patients receiving H2RA therapy went an
entire week without repletion versus patients receiving PPI.
Although the magnitude or frequency of potassium or cal-
cium repletion were generally higher among PPI users, these
differences were not statistically signiﬁcant. The number of
patients with evidence of infection was not signiﬁcantly
different between groups. Compared to patients on H2RA
therapy, signiﬁcantly more patients receiving PPI reported GI
symptoms.
H2RA therapy deserves serious consideration in place of PPI,
when possible, for HCT patients post-discharge.
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Background: Multidisciplinary collaboration leads to
improvement in pt outcomes when clinical pharmas are
engaged in various settings. Clinical pharma integration in
the BMT setting has increased as these programs expand.
There is an absence of literature deﬁning the beneﬁt of
clinical pharma involvement in this area of practice. UMass
Memorial Medical Center is a large academic medical center
performing 108 allogenic transplants since 2010. In August
2010, the medical center implemented the integration of a
health-system clinical pharma to the BMT team. This study
aims to determine the impact of a health- system based
clinical pharma on pt outcomes and associated costs in the
BMT setting.
Methods: Records for pts receiving an allogeneic stem cell
transplant (ASCT) from January 2008 to August 2012 were
reviewed. The primary outcome measure was difference in
length of stay (LOS) for ASCT prior to and after pharma
integration on the BMT team. Secondary outcome measures
include number of readmissions within 30 days, overall
survival at 100 days, duration of intravenous (IV) antimi-
crobial therapy, duration of IV immunosuppressive therapy
(IST), and duration of oral IST.
Results: 106 pts were identiﬁed and included for analysis. 45
were transplanted prior to pharmacist implementation and
61 were after BMT. Baseline demographics were similar be-
tween the two groups. In the pre and post group, the most
common indication for transplant was AML (40% vs. 51%) and
the most common source was a matched unrelated donor
(60% vs. 62%). The majority of pts in both groups received
myeloablative regimens (80% vs. 69%). LOS was decreased in
the after group but was not statistically signiﬁcant (24.8 vs.
22.9 days, p¼ 0.43).100-day survival (80% vs. 88.5%, p¼0.23)
and readmission within thirty days were not signiﬁcantly
changed (42.2% vs. 37.7%, p¼0.64). Days of IV antibacterials,
antivirals and antifungals were all decreased, but were not
statistically signiﬁcant. Days on IV IST were signiﬁcantly
decreased (21.4 vs. 11.3 days, p¼0.001) showing a reciprocal
increase in oral IST use (4.9 vs. 9.1 days, p¼0.001). Costs
beneﬁts were assessed using 2013 WAC prices. Cost savings
were reported as $3,083 per pt, for a total beneﬁt since
implementation of $184,985 or $92,493 per year.
Conclusion: Our analysis demonstrates signiﬁcant im-
provements in cost saving with the implementation of a
pharma in the BMT setting, speciﬁcally allogeneic pts. While
